Locked content DF Capital looking to float another Chinese firm on the WSE

DF Capital is foreshadowing the entry of another Chinese company onto the Warsaw Stock Exchange. DF Capital CEO Jarosław Dąbrowski said that “the Polish capital market is past its bullish phase and it’s necessary to count on organic growth and niche filling, as well as consolidations....

Locked content Fenghua to make WSE debut

Upon entry onto the Frankfurt and Warsaw exchanges, Fenghua SoleTech will not increase the amount of free float shares, which will reach 10.7 percent. The company aims to become China’s number one shoe sole producer, at the same time aiming to pay out dividends in the range of 10-20 percent of...

Locked content CDRL sets share price in IPO

CDRL, the owner of children’s clothing brand Cocodrillo, has set its IPO share price at PLN 14.90 apiece, the company said in a statement on Thursday. This puts the value of the offer at PLN 14.9 million. The company will issue 1 million shares for the purpose of the IPO, 920,000 of which will be...

Locked content Helix BioPharma mulls WSE debut

Helix BioPharma, a Canadian pharmaceutical firm with Polish sharholders, may carry out an IPO on the Warsaw Stock Exchange within the next 12 months, the company’s CEO Robert Verhagen told daily Parkiet. The company is now listed in Toronto and in Frankfurt. “We don’t just want another dual listing....

Locked content Perma Fix Medical plans main market debut in Q1

Perma Fix Medical, a unit of the Perma Fix Environmental Services capital group, would like to debut on the main market of the Warsaw Stock Exchange in Q1 2015, the company’s CEO Louis Centofanti told ISBnews. “We will soon start work on an issue prospectus and a move to the main market of the WSE,”...

Locked content Milestone Medical plans main market IPO

US-based innovative medical devices producer Milestone Medical will soon submit a prospectus to the Polish Financial Supervision Authority, as its plans to move listing from the NewConnect market to the main market of the Warsaw Stock Exchange, the company’s CEO Leonard Osser told ISBnews. “We want ...

Locked content Biomed-Lublin headed for WSE main market

Medical preparations and pharmaceuticals producer Biomed-Lublin plans to move from the NewConnect market to the main market of the Warsaw Stock Exchange. The company said on Friday that it has submitted an issue prospectus to the Financial Supervision Authority. It is not planning a new share issue ...